Vascular Health and Risk Management

We are pleased to announce a new Article Collection in Vascular Health and Risk Management, dedicated to the role of anti-diabetic drugs in the management of cardiovascular risk.

While anti-diabetic drugs are widely used in clinical practice for blood sugar control and to delay complications of diabetes, several anti-diabetic drugs – including GLP-1 receptor agonists and SGLT2 inhibitors – have also been shown to prevent adverse cardiovascular events and cardiovascular mortality.

Anti-diabetic drugs thus have an important role to play in cardiovascular medicine, with considerable potential for preventing further cardiac events in select populations.

To highlight this important area of research, Vascular Health and Risk Management invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of anti-diabetic therapies in the context of cardiovascular disease (CVD).

The Collection, edited by Editor-In-Chief Professor Roland Asmar, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections that highlight breakthrough therapies, drugs, or technologies that have the potential to lead to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis, increasing the discoverability and visibility of your research.

While the call is open to receive manuscripts across the broad spectrum of antidiabetic drugs in the management of cardiovascular risk, the Editors are particularly interested in papers relating to the following areas:

• Risk factors for diabetes and CVD
• Mechanisms of cardiovascular protection for modern anti-diabetic treatments
• Clinical studies uncovering the efficacy and safety of antidiabetic drugs in CVD
• Epidemiological studies of CVD patients taking anti-diabetic medications

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Please review the journal scope and author submission instructions prior to submitting a manuscript. Submitting authors are eligible for a 20% discount on the Article Publishing charge. Please use the promo code BWOME when prompted during the submission.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 January 2026.

Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Roland Asmar, Foundation-Medical Research Institutes (F-MRI), Switzerland

View all papers in this article collection

We are pleased to announce a new Article Collection in Vascular Health and Risk Management, dedicated to the game-changing role of pharmacotherapy in the management of heart failure. Since their clinical introduction, heart failure medications have revolutionized patient care, leading to improved survival, reduced hospitalization and improved quality of life in eligible patients, especially in those with reduced ejection fraction.

Given the global importance of pharmacotherapy in managing heart failure, Vascular Health and Risk Management invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of these transformative therapies.

The collection, edited by Editor-In-Chief Professor Roland Asmar, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

While the call is open to receive manuscripts across the broad spectrum of pharmacotherapy in the management of heart failure, the Editors are particularly interested in papers in the following areas:

• Heart failure pathophysiology as it relates to potential therapeutic targets
• Emerging drugs for acute and chronic heart failure
• Efficacy and safety of heart failure pharmacotherapy, with special attention given to studies on patients with comorbidities
• Papers focused on the implementation of heart failure medications in clinical practice

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Please review the journal scope and author submission instructions prior to submitting a manuscript. Submitting authors are eligible for a 20% discount on the Article Publishing charge. Please use the promo code VBOLK when prompted during the submission.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 January 2026.

Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Roland Asmar, Foundation-Medical Research Institutes (F-MRI), Switzerland

View all papers in this article collection

We are pleased to announce a new Article Collection in Vascular Health and Risk Management, dedicated to the promising role of renal denervation in the treatment of hypertension. Renal denervation offers a new, minimally invasive option for patients with uncontrolled hypertension, effectively lowering blood pressure and potentially reducing the need for, or dosage of, antihypertensive medications.

Given the emerging importance of renal denervation in managing hypertension, Vascular Health and Risk Management invites submissions of original research articles, reviews, and perspectives exploring the clinical efficacy, safety, mechanisms of action, and real-world application of this transformative therapy.

The Collection, edited by Editor-In-Chief Professor Roland Asmar, will be included in Taylor & Francis’ Game Changer Series. This series features Article Collections focused on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis, increasing the discoverability and visibility of your research.

While the call is open to receive manuscripts across the broad spectrum of renal denervation in hypertension, the Editors are particularly interested in manuscripts relating to the following areas:

• The physiology of renal denervation in the treatment of hypertension
• Strengths and limitations of current renal denervation technologies
• Identification and evaluation of appropriate patients, including biomarkers and phenotype
• Advances in technologies, including catheter design, ultrasound, and radiofrequency
• Endpoint selection in clinical trials
• Long-term efficacy and safety studies

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Please review the journal scope and author submission instructions prior to submitting a manuscript. Submitting authors are eligible for a 20% discount on the Article Publishing charge. Please use the promo code OMDLY when prompted during the submission.

Please submit your manuscript on our website. The deadline for submitting manuscripts is 1 January 2026.

Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisor

Roland Asmar, Foundation-Medical Research Institutes (F-MRI), Switzerland

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Vascular calcification in health and disease", in Vascular Health and Risk Management.

Calcification plays a significant role in the development and progression of vascular disease. It involves the abnormal deposition of calcium phosphate crystals within the vascular intimal or medial layer. Intimal calcification is commonly associated with atherosclerosis, a condition in which plaque builds up inside the arteries, leading to reduced elasticity and narrowed vessels. Intimal calcification is typically linked with inflammation and plaque rupture, contributing to acute cardiovascular events such as heart attacks. Vascular calcification can also occur in the medial layer of blood vessels. Medial calcification, more common in the ageing population, and in patients suffering from diabetes and chronic kidney disease, leads to arterial stiffening and increased systolic blood pressure. While once considered a passive process, calcification is now recognized as an actively regulated, cell-mediated phenomenon involving osteogenic signaling pathways. Understanding the mechanisms behind vascular calcification is crucial for developing targeted therapies to mitigate its impact on cardiovascular health.

Studying vascular calcification is crucial because it is a key contributor to cardiovascular morbidity and mortality, particularly in ageing populations and patients with chronic conditions like diabetes and chronic kidney disease. Vascular calcification is associated with arterial stiffness, reduced vessel elasticity, and increased risk of hypertension, heart attacks, and stroke. Despite its clinical significance, there are currently no effective therapies that specifically target or reverse vascular calcification. Understanding the underlying molecular and cellular mechanisms, such as the transformation of vascular smooth muscle cells into osteoblast-like cells, can help identify potential therapeutic targets. Additionally, early detection and improved imaging techniques can aid in risk stratification and treatment planning for patients. Given its active, regulated nature, vascular calcification represents a promising area for intervention. Studying it not only deepens our understanding of vascular biology but also has the potential to improve outcomes for millions of patients affected by cardiovascular disease worldwide.

This Article Collection seeks contributions that address the following key areas:

• Genetics of vascular calcification
• Intimal vs medial calcification
• Cell biological and molecular pathways of vascular calcification
• Biomarkers for the detection of vascular calcification
• Detection of vascular calcification by clinical imaging modalities (MSCT, PET/ SPECT)
• Clinical significance of vascular calcification - Is calcification good or bad?
• Pharmacological treatment of vascular calcification
• Nutraceutical intervention of vascular calcification

Keywords

• Calcification
• MGP
• Vitamin K.
• Treatment trials
• Vascular smooth muscle cells

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code 04D4D to indicate that your submission is for consideration in this Article Collection. Please note that normal Article Processing Charges will apply.

The deadline for submitting manuscripts is 28 February 2026.

Please contact Zhiyuan Zhang at [email protected] with any queries regarding this Article Collection.

Guest Advisors

Peter W de Leeuw, Maastricht University Medical Center, The Netherlands

[email protected]

Peter W de Leeuw is emeritus professor of Medicine at Maastricht University and has a life-long history of research in hypertension. He has been a member of the Council of the ISH and has served as an Editorial Board member of several hypertension journals. His present research interest is in vascular calcification and in fibromuscular dysplasia.

Leon Schurgers, Maastricht University, The Netherlands

[email protected]

Leon Schurgers is chair and professor of Biochemistry at Maastricht University and has a life-long history of research in vascular remodeling. His present research interest is in vascular calcification and vascular smooth muscle cell phenotype switching.

View all papers in this article collection